Cargando…

Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis

BACKGROUND: Acute pancreatitis (AP) is a multifactorial disease that is associated with substantial morbidity and mortality. Thrombosis and inflammation are involved in the development and progression of AP. AIM: To develop and validate a novel and simple scoring system for predicting 28-day adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tianyong, Cheng, Tao, Liao, Ye, He, Yarong, Liu, Bofu, Lai, Qiang, Pan, Pan, Liu, Junzhao, Lei, Chenxi, Cao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769056/
https://www.ncbi.nlm.nih.gov/pubmed/35068938
http://dx.doi.org/10.2147/JIR.S344446
_version_ 1784635043531980800
author Han, Tianyong
Cheng, Tao
Liao, Ye
He, Yarong
Liu, Bofu
Lai, Qiang
Pan, Pan
Liu, Junzhao
Lei, Chenxi
Cao, Yu
author_facet Han, Tianyong
Cheng, Tao
Liao, Ye
He, Yarong
Liu, Bofu
Lai, Qiang
Pan, Pan
Liu, Junzhao
Lei, Chenxi
Cao, Yu
author_sort Han, Tianyong
collection PubMed
description BACKGROUND: Acute pancreatitis (AP) is a multifactorial disease that is associated with substantial morbidity and mortality. Thrombosis and inflammation are involved in the development and progression of AP. AIM: To develop and validate a novel and simple scoring system for predicting 28-day adverse outcomes in AP patients based on a thrombotic and an inflammatory biomarker. METHODS: A single-center, retrospective cohort study was used to establish the new scoring system (thrombo-inflammatory prognostic score; TIPS), and another study was used to verify it. The study end points were 28-day mortality, requirement for mechanical ventilation (MV), persistent organ failure (POF), and admission to the intensive care unit (AICU). Receiver operating characteristic (ROC) curves was drawn to validate the predictive value of the TIPS. The performance of the TIPS was compared with that of conventional predictive scoring systems. Logistic regression models were used to investigate the relationship between the TIPS and the different end points. RESULTS: Among 440 patients with AP in the derivation group, 27 patients died within the 28-day follow-up period. Prothrombin time (PT) and interleukin-6 (IL-6) were used to calculate the TIPS. The TIPS (AUC=0.843) showed a performance comparable to that of the more established APACHE II (AUC=0.841), SOFA (AUC=0.797), BISAP (AUC=0.762), and Balthazar CT (AUC=0.655) in predicting 28-day mortality in AP. The 28-day mortality and the incidence of MV, POF, and AICU were significantly higher among patients with a higher TIPS (P<0.001). The results of logistic regression analyses indicated that the TIPS was independently associated with the risks of 28-day mortality, AICU, MV and POF. CONCLUSION: The TIPS can enable prediction of 28-day adverse clinical outcomes with AP patients in the ED.
format Online
Article
Text
id pubmed-8769056
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87690562022-01-20 Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis Han, Tianyong Cheng, Tao Liao, Ye He, Yarong Liu, Bofu Lai, Qiang Pan, Pan Liu, Junzhao Lei, Chenxi Cao, Yu J Inflamm Res Original Research BACKGROUND: Acute pancreatitis (AP) is a multifactorial disease that is associated with substantial morbidity and mortality. Thrombosis and inflammation are involved in the development and progression of AP. AIM: To develop and validate a novel and simple scoring system for predicting 28-day adverse outcomes in AP patients based on a thrombotic and an inflammatory biomarker. METHODS: A single-center, retrospective cohort study was used to establish the new scoring system (thrombo-inflammatory prognostic score; TIPS), and another study was used to verify it. The study end points were 28-day mortality, requirement for mechanical ventilation (MV), persistent organ failure (POF), and admission to the intensive care unit (AICU). Receiver operating characteristic (ROC) curves was drawn to validate the predictive value of the TIPS. The performance of the TIPS was compared with that of conventional predictive scoring systems. Logistic regression models were used to investigate the relationship between the TIPS and the different end points. RESULTS: Among 440 patients with AP in the derivation group, 27 patients died within the 28-day follow-up period. Prothrombin time (PT) and interleukin-6 (IL-6) were used to calculate the TIPS. The TIPS (AUC=0.843) showed a performance comparable to that of the more established APACHE II (AUC=0.841), SOFA (AUC=0.797), BISAP (AUC=0.762), and Balthazar CT (AUC=0.655) in predicting 28-day mortality in AP. The 28-day mortality and the incidence of MV, POF, and AICU were significantly higher among patients with a higher TIPS (P<0.001). The results of logistic regression analyses indicated that the TIPS was independently associated with the risks of 28-day mortality, AICU, MV and POF. CONCLUSION: The TIPS can enable prediction of 28-day adverse clinical outcomes with AP patients in the ED. Dove 2022-01-15 /pmc/articles/PMC8769056/ /pubmed/35068938 http://dx.doi.org/10.2147/JIR.S344446 Text en © 2022 Han et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Han, Tianyong
Cheng, Tao
Liao, Ye
He, Yarong
Liu, Bofu
Lai, Qiang
Pan, Pan
Liu, Junzhao
Lei, Chenxi
Cao, Yu
Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title_full Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title_fullStr Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title_full_unstemmed Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title_short Development and Validation of a Novel Prognostic Score Based on Thrombotic and Inflammatory Biomarkers for Predicting 28-Day Adverse Outcomes in Patients with Acute Pancreatitis
title_sort development and validation of a novel prognostic score based on thrombotic and inflammatory biomarkers for predicting 28-day adverse outcomes in patients with acute pancreatitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769056/
https://www.ncbi.nlm.nih.gov/pubmed/35068938
http://dx.doi.org/10.2147/JIR.S344446
work_keys_str_mv AT hantianyong developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT chengtao developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT liaoye developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT heyarong developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT liubofu developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT laiqiang developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT panpan developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT liujunzhao developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT leichenxi developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis
AT caoyu developmentandvalidationofanovelprognosticscorebasedonthromboticandinflammatorybiomarkersforpredicting28dayadverseoutcomesinpatientswithacutepancreatitis